source
- Blood centers poised to boost cell and gene therapy supply chainsBlood centers have the donors, resources and community footprint that drug sponsors need to address supply chain bottlenecks for cell and gene therapies. Cell and gene therapies such as CAR‑T and…
- FDA approves first radioligand generic, pitting Curium against Novartis' LutatheraThe U.S. Food and Drug Administration has granted approval to Curium’s radioligand product, the first generic in this therapeutic class. The approved drug is a direct equivalent of Novartis’ Lutat…